Fucoidan from

Femke Hacker, Johann Roider, Alexa Klettner, Philipp Dörschmann

Abstract read

In one paragraph

Article in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Femke HackerDepartment of Ophthalmology, University Medical Center, Kiel University, Arnold-Heller-Str. 3, Haus B2, 24105 Kiel, Germany.

Johann RoiderDepartment of Ophthalmology, University Medical Center, Kiel University, Arnold-Heller-Str. 3, Haus B2, 24105 Kiel, Germany.

Alexa KlettnerDepartment of Ophthalmology, University Medical Center, Kiel University, Arnold-Heller-Str. 3, Haus B2, 24105 Kiel, Germany.ORCID 0000-0002-2709-1059

Philipp DörschmannDepartment of Ophthalmology, University Medical Center, Kiel University, Arnold-Heller-Str. 3, Haus B2, 24105 Kiel, Germany.ORCID 0009-0001-7062-9918

Funding

Retinologische Gesellschaft - Dr. Gaide-AMD-Preis not available

6 · The paper itself

Abstract

Fucoidans are natural compounds that exhibit bioactivity against age-related macular degeneration (AMD), the leading cause of central vision loss in industrialized nations. Pathological factors like oxidative stress and lipid peroxidation play vital roles in AMD pathogenesis. Lipid-induced alterations in the retinal pigment epithelium (RPE) contribute to AMD development. In this study, a commercial fucoidan from

Indexed as

FucusMacular DegenerationPolysaccharidesRetinal Pigment EpitheliumAnimalsCell LineCell SurvivalHumansInterleukin-8Lipid PeroxidationOxidative StressReactive Oxygen SpeciesSwineVascular Endothelial Growth Factor AfucoidanInterleukin-8PolysaccharidesReactive Oxygen SpeciesVascular Endothelial Growth Factor Aage-related macular degeneration (AMD)erastinfucoidanglutathione peroxidase 4 (GPX4)interleukinlipid peroxidationlipotoxicityretinal pigment epithelium (RPE)retinoid isomerohydrolase (RPE65)vascular endothelial growth factor (VEGF)

Identifiers

PMID41745467

DOI10.3390/md24020064

PMCPMC12942446

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.